Modulation of adjuvant arthritis (AA) development after nasal treatment with matrix metalloproteinase (MMP) peptides after AA induction

Copyright information:Taken from "Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration"Arthritis Research 2002;4(4):R2-R2.Published online 7 May 2002PMCID:PMC125294.Copyright © 2002 Wagner et al., licensee BioMed Central Ltd The nasal treatment was started at day +11, after immunization with , when more than 50% of the animals showed weight loss (i.e. at the onset of clinical arthritis). The nasal treatment was repeated four times (arrows). Data shown are mean arthritis scores ± standard error of the mean of five rats (MMP-10 and MMP-16 peptide groups) or 10 rats (MMP-3 peptide group) per group. OVA, ovalbumin peptide.